Drug Trial Radar · NCT05714085
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
342
Planned (sponsor's estimate)
Start
May 31, 2023
Primary completion
Aug 20, 2029
Study completion May 12, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 29 days, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Conditions
- Heart Failure
- Left Ventricular Systolic Dysfunction
Interventions
Vericiguat tabletDrug
2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
Vericiguat suspensionDrug
0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
Placebo tabletDrug
Placebo for vericiguat administered orally once daily in tablet form
Placebo suspensionDrug
Placebo for vericiguat administered orally once daily in suspension form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Base Period: Change from baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)Time frame: Baseline and Week 16 of Base Period
- Extension Period: Percentage of participants with one or more adverse events (AEs)Time frame: Includes data collected up to a maximum of approximately 8 years
- Extension Period: Percentage of participants who discontinued study drug due to an AETime frame: Includes data collected up to a maximum of approximately 8 years
Locations
112 sites in 30 countries. Site status is shown where the registry gives one.
The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002)
Los Angeles, California · Recruiting
Lucile Packard Children's Hospital ( Site 0040)
Palo Alto, California · Recruiting
Loma Linda University Health System ( Site 0008)
San Bernardino, California · Recruiting
Children's Hospital Colorado ( Site 0012)
Aurora, Colorado · Completed
Children's National Medical Center ( Site 0020)
Washington D.C., District of Columbia · Recruiting
Johns Hopkins All Children's Hospital ( Site 0029)
St. Petersburg, Florida · Recruiting
Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001)
Atlanta, Georgia · Recruiting
Boston Children's Hospital ( Site 0035)
Boston, Massachusetts · Recruiting
C.S. Mott Children's Hospital ( Site 0033)
Ann Arbor, Michigan · Recruiting
Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006)
St Louis, Missouri · Recruiting
Columbia University Medical Center-Pediatric Cardiology ( Site 0016)
New York, New York · Recruiting
The Children's Hospital at Montefiore ( Site 0030)
The Bronx, New York · Recruiting
Cincinnati Children's Hospital Medical Center ( Site 0034)
Cincinnati, Ohio · Recruiting
Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022)
Cleveland, Ohio · Recruiting
Children's Hospital of Philadelphia (CHOP) ( Site 0004)
Philadelphia, Pennsylvania · Recruiting
Children's Hospital of Pittsburgh ( Site 0010)
Pittsburgh, Pennsylvania · Recruiting
Le Bonheur Children's Hospital ( Site 0007)
Memphis, Tennessee · Recruiting
Children's Health-The Heart Center ( Site 0015)
Dallas, Texas · Recruiting
Texas Children's Hospital ( Site 0039)
Houston, Texas · Recruiting
Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019)
Seattle, Washington · Recruiting
Centre Hospitalier Régional de la Citadelle ( Site 0302)
Liège, Liege, Belgium · Completed
UZ Gent ( Site 0301)
Ghent, Oost-Vlaanderen, Belgium · Recruiting
UZ Leuven ( Site 0300)
Leuven, Vlaams-Brabant, Belgium · Recruiting
Incor - Instituto do Coracao ( Site 0400)
São Paulo, Brazil · Recruiting
Instituto Dante Pazzanese de Cardiology ( Site 0402)
São Paulo, São Paulo, Brazil · Recruiting
Stollery Children's Hospital ( Site 0501)
Edmonton, Alberta, Canada · Recruiting
The Hospital for Sick Children ( Site 0500)
Toronto, Ontario, Canada · Recruiting
Centre intégré universitaire de santé et de services sociaux-Centre de recherche du CHUS ( Site 0502)
Sherbrooke, Quebec, Canada · Recruiting
Clinica Somer ( Site 0607)
Rionegro, Antioquia, Colombia · Recruiting
Ciensalud Ips S A S ( Site 0608)
Barranquilla, Atlántico, Colombia · Recruiting
Fundación Cardioinfantil Instituto de Cardiología ( Site 0603)
Bogotá, Bogota D.C., Colombia · Recruiting
Fundación Valle del Lili ( Site 0604)
Cali, Valle del Cauca Department, Colombia · Recruiting
Clínica Imbanaco S.A.S ( Site 0602)
Cali, Valle del Cauca Department, Colombia · Recruiting
Klinički bolnički centar Zagreb ( Site 3700)
Zagreb, City of Zagreb, Croatia · Recruiting
Rigshospitalet-BørneUngeAfdelingen ( Site 0800)
Copenhagen, Capital Region, Denmark · Recruiting
Tampereen yliopistollinen sairaala-Pediatric Early Phase Trials Unit ( Site 0900)
Tampere, Pirkanmaa, Finland · Recruiting
Hôpital Universitaire Necker Enfants Malades ( Site 1001)
Paris, France · Completed
Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universita ( Site 1004)
Paris, France · Completed
CHU Bordeaux Haut-Leveque ( Site 1000)
Pessac, Aquitaine, France · Completed
Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1002)
Nantes, Loire-Atlantique, France · Completed
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.